News

ARCHIVE

IMBRIUM THERAPEUTICS PRESENTS FIRST DATA AND DESCRIBES NOVEL MECHANISM OF ACTION FOR IMB-115, A POTENTIAL FIRST-IN-CLASS TREATMENT FOR INSOMNIA DISORDER, AT 34^th ANNUAL SLEEP MEETING

IMBRIUM THERAPEUTICS L.P. AND SPINETHERA, INC. ANNOUNCE FIRST PATIENT DOSED IN PHASE 1/2 CLINICAL STUDY

IMBRIUM THERAPEUTICS COMPLETES FIRST PATIENT DOSED IN PHASE 2 STUDY TO EVALUATE SUNOBINOP FOR THE POTENTIAL TREATMENT OF ALCOHOL USE DISORDER
Imbrium Therapeutics Submits Investigational New Drug Application to Evaluate Sunobinop for the Potential Treatment of Alcohol Use Disorder
Imbrium Therapeutics Achieves Last Patient Last Visit in Clinical Trial of Potential Treatment for Overactive Bladder Syndrome

Imbrium Therapeutics Completes First Patient Visit in Phase 1 Study of Potential Treatment for Interstitial Cystitis/Bladder Pain Syndrome
Imbrium Therapeutics Presents Results of a Phase 2 Study of Sunobinop at 33rd American Academy of Addiction Psychiatry Annual Meeting

Imbrium Therapeutics L.P. Exercising Option with PureTech Health to Develop and Commercialize a Non-Opioid Interstitial Cystitis/Bladder Pain Syndrome Treatment

Imbrium Therapeutics Announces First Patient Dosed in Phase 2 Study of Potential First-in-Class Molecule for Insomnia Associated with Alcohol Cessation
Imbrium Therapeutics L.P. and SpineThera Announce Issuance of U.S. Patent Covering Composition of Matter Protection for SX600, a Non-Opioid Product in Development for Epidural Steroid Injection for the Treatment of Low Back Pain
Imbrium Therapeutics Advances Insomnia Pipeline Through Initiation of a Phase 2 Study of Potential First-in-Class Molecule for Insomnia Associated with Alcohol Cessation
Imbrium Therapeutics Announces U.S. FDA Orphan Drug Designation for Tinostamustine for the Treatment of T-cell Prolymphocytic Leukemia
Imbrium Therapeutics Announces Enrollment of the First Patient in Expansion Phase of Tinostamustine Trial in Patients with Difficult-to-Treat Blood Cancers